Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Xelstrym™(dextroamphetamine) – New drug approval
March 23, 2022 - Noven Therapeutics announced the FDA approval of Xelstrym (dextroamphetamine), for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older.
